A comprehensive view of Karuna Therapeutics Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Bristol Myers Squibb acquires Karuna Therapeutics; Bristol Myers gains potential first-in-class schizophrenia treatment KarXT with multi-billion dollar sales potential and moves it into the neuroscience market
Published: March 18, 2024 by Bristol-Myers Squibb Co.
Bristol Myers Squibb acquires biopharmaceutical company Karuna Therapeutics for US$14.0B; the acquisition includes Karuna's KarXT, a potential treatment for schizophrenia and Alzheimer's disease psychosis
Published: January 03, 2024 by Outsourcing-Pharma.com
Bristol Myers Squibb strengthens neuroscience portfolio with acquisition of Karuna Therapeutics in deal with total equity value of US$14.0B; Karuna’s lead asset is antipsychotic KarXT xanomeline-trospium
Published: December 22, 2023 by Bristol-Myers Squibb Co.

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count